Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia.
METHODS
The incidence and risk factors for erythromycin-induced ototoxicity are unknown. We conducted a prospective, nested case-control study of assessment of auditory function in patients receiving erythromycin versus other antibiotics (control group) for community-acquired pneumonia. Sequential audiograms were performed during antibiotic therapy for both cases and controls by an audiologist unaware of the identity of the therapy administered. Erythromycin serum concentrations were obtained for all patients receiving erythromycin.


RESULTS
Symptomatic ototoxicity (tinnitus or hearing loss) confirmed by audiograms was documented in five of 30 patients receiving erythromycin and none of 15 receiving other antibiotics. Ototoxicity was significantly related to high peak concentration and high AUC 0-infinity as a function of decreased total systemic clearance. Ototoxicity occurred only in those patients who received 4 g/day versus 2 g/day or no erythromycin (p = 0.05). Ototoxicity resolved in all patients within 6 to 14 days after discontinuation of therapy.


CONCLUSIONS
Erythromycin ototoxicity is dose- and serum concentration-dependent. Patients receiving erythromycin, especially at a total daily dose of 4 g, should be monitored regularly for subjective evidence of sensorineural hearing dysfunction. Ototoxicity is reversible if the diagnosis is made early in the course.
Swanson
D J
DJ
Department of Pharmacy Practice, Veterans Administration Medical Center, Pittsburgh, Pennsylvania.
Sung
R J
RJ
Fine
M J
MJ
Orloff
J J
JJ
Chu
S Y
SY
Yu
V L
VL
D000328:Adult; D000368:Aged; D001299:Audiometry; D016022:Case-Control Studies; D004917:Erythromycin / Q000009:adverse effects* / Q000493:pharmacokinetics; D006311:Hearing Disorders / Q000097:blood / Q000139:chemically induced*; D006312:Hearing Loss, Bilateral / Q000139:chemically induced; D006319:Hearing Loss, Sensorineural / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D014012:Tinnitus / Q000139:chemically induced
D004917:Erythromycin